6 June 2023 - NICE is unable to make a recommendation on the use of esketamine hydrochloride (Spravato) for the treatment ...
6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone ...
2 June 2023 - NICE’s final draft guidance recommends mavacamten (Camzyos, Bristol-Myers Squibb) as an add-on to standard care that ...
31 May 2023 - NICE has published evidence based recommendations on the use of mosunetuzumab (Lunsumio) for the treatment of ...
31 May 2023 - NICE has published evidence-based recommendations on the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclyxto) ...
31 May 2023 - NICE has for the first time recommended an oral treatment for preventing migraines. ...
29 May 2023 - A family has raised £12,000 to pay for a cancer drug for their mother, which was ...
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...
18 May 2023 - The NICE recommendation is based on data from three Phase 3 clinical trials demonstrating upadacitinib achieved ...
18 May 2023 - Up to 150,000 people in England with a type of chronic heart failure are set to ...
17 May 2023 - NICE has published evidence-based recommendations on the use of difelikefalin acetate (Kapruvia) for the treatment of ...
17 May 2023 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for patients 16 years of ...
4 May 2023 - Negotiations for a new voluntary scheme for branded medicines pricing to open between the government, NHS ...
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 ...